Thursday, May 22, 2014 3:21:10 PM
The patent the company has acquired, ( http://ih.advfn.com/p.php?pid=nmona&article=60415236 ) is about 5 years old and needs to go through testing and FDA trials before approval. That will take some time.
There is a period that the patent holder has exclusive on the product, but it's from the date of patent issue and not production. After that, generics kick in with no compensation.
North County Clinical Research ( http://ih.advfn.com/p.php?pid=nmona&article=61887961 ) looks OK, but small. What
BioRegenerative Sciences has to offer is IMHO, questionable.
My brief research on them shows them to be like a hair club for women. Not sure how they would fit in.
The oil and gas PR's are over the top. The supply is tightly controlled as are all form of distribution. Contracts are generally long term and buyers stick to reputable suppliers to ensure continued supply. This company doesn't have the funds to deal in that sector. The 50m funding from the bone cruncher wouldn't be enough to start.
PR's like the oil one don't work anymore. That may have caused a run 10 years ago, but investors are getting smarter.
It really doesn't help that the company has a history of failure and a rising OS. Those 144 filings don't help either.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM